Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × padeliporfin × Clear all

Phase

Status

Terminated 2 Completed 2 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Transitional Cell Cancer of Renal Pelvis and Ureter 1

Interventions

pembrolizumab 525 Specimen Handling 431 Carboplatin 397 Magnetic Resonance Spectroscopy 387 Cisplatin 367 Cyclophosphamide 351 Radiotherapy 325 Gemcitabine 277 Bevacizumab 270 Paclitaxel 259 Biopsy 253 Drug Therapy 245 Blood Specimen Collection 225 venetoclax 208 Nivolumab 204 fludarabine 202 Capecitabine 201 Oxaliplatin 196 Docetaxel 188 Injections 181 Fluorouracil 174 Radiosurgery 163 Dexamethasone 163 Rituximab 145 Pemetrexed 143 Standard of Care 137 Surgical Procedures, Operative 136 durvalumab 130 atezolizumab 128 tislelizumab 124

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620239 2026-02-04

UCM301

Steba Biotech S.A.

Phase 3 Recruiting

Transitional Cell Cancer of Renal Pelvis and Ureter

Data powered by HemOnc (CC BY 4.0) Colophon ⚡